Skip to main content

Eli Lilly

(LLY) - Get Eli Lilly and Company Report

received Food and Drug Administration clearance to sell its attention-deficit hyperactivity treatment, Strattera.

The company hopes to have the drug on the market by January.

TheStreet Recommends

The approval was pressuring shares of

Shire Pharmaceuticals


, which sells the hyperactivity treatment Adderall. Lilly's treatment is believed to be less likely to be abused because it isn't a stimulant.

Lilly's shares ended down about 6% at $64 Tuesday after the company said it's cautious about its earnings prospects for 2003. They were about 3% higher at $66 on the Instinet premarket session Wednesday. Shire's shares were off 12% at $20.94.